HOME >> BIOLOGY >> NEWS
Einstein researchers' prototype vaccine could provide improved protection against tuberculosis

(BRONX, NY) -- Using a novel approach, researchers at the Albert Einstein College of Medicine of Yeshiva University have developed a prototype vaccine against tuberculosis (TB) that works better in animal models than the only TB vaccine now available. In this era of multi-drug resistant TB and growing numbers of people with active TB due to coinfection with HIV, the advance could herald a needed breakthrough against one of the worlds leading killers. Their study appears in the August issue of the Journal of Clinical Investigation.

TB is caused by Mycobacterium tuberculosis, a bacterial species that infects one third of the worlds population (up to 10% of whom will develop active TB) and causes up to three million deaths annually. The only available vaccine--known as Bacille Calmette-Gurin (BCG)is a live, attenuated (weakened) strain of M. bovis, which causes TB in cattle. Despite being the worlds most widely used vaccine, BCG fails to protect adults from TB infection and doesnt reliably stem the reactivation of pulmonary TB (the most common form of the disease) in adults.

Virtually all efforts to develop a better TB vaccine have focused on boosting BCGmodifying it to elicit a stronger immune response in people, says Dr. William Jacobs, Jr., co-senior author of the paper and a Howard Hughes Medical Institute investigator at Einstein as well as professor of microbiology & immunology and molecular genetics. But we feel that tweaking the marginally useful BCG vaccine is the wrong strategy. So weve started with virulent M. tuberculosisthe organism that actually causes TB in humansand are knocking out certain genes to yield a live, attenuated M. tuberculosis strain that still produces a strong immunological response that protects people.

TB bacteria invade human cells and then--successfully evading a persons immune response--lurk inside cells and multiply. A key evasion strategy involves preventing their host cells from undergoing apopto
'"/>

Contact: Larry Katzenstein
lkatzens@aecom.yu.edu
718-430-3101
Albert Einstein College of Medicine
1-Aug-2007


Page: 1 2 3

Related biology news :

1. In a first, Einstein scientists discover the dynamics of transcription in living mammalian cells
2. Einstein researchers discover radiation-eating fungi
3. Einsteins Dr. Vern Schramm elected to the National Academy of Sciences
4. Einstein researchers discover how a key dietary vitamin is absorbed
5. NCI funds Einstein and U. Albany NanoCollege to make worlds smallest cancer detection device
6. Team at CNSE and Einstein receive grant to develop worlds smallest cancer detection device
7. Einstein researchers demonstrate a novel approach to treating AIDS
8. Einsteins Dr. E. Richard Stanley receives 2006 E. Donnall Thomas Prize
9. Einstein researchers find key to unlocking worlds deadliest malaria parasite
10. Findings by Einstein scientists reveal possible strategy against obesity, diabetes and infertility
11. Einstein researchers take the pulse of a gene in living cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... SPRING, Md. and RESEARCH TRIANGLE ... United Therapeutics Corporation (NASDAQ: UTHR ) today ... of up to $250 million of the company,s common ... remain open through December 31, 2017. Purchases may be ... in privately negotiated transactions from time to time as ...
(Date:4/27/2017)... ... April 27, 2017 , ... Arrowhead Publishers is pleased to ... coming to San Diego, CA on September 27-28, 2017. Leaders from the pharmaceutical, ... advances in the treatment of various types of pain. There are also extended ...
(Date:4/27/2017)... ... April 27, 2017 , ... The ... Communication Award goes to Jayson Lusk, a consummate communicator who promotes agricultural science ... advocate for science, as he explains how innovation and growth in agriculture are ...
(Date:4/26/2017)... ... April 26, 2017 , ... Led by ... I clinical trials comes to Tampa, San Francisco and Boston in 2017. ... FDA regulated organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., Ocular Therapeutix ...
Breaking Biology Technology:
Cached News: